BioCentury
ARTICLE | Clinical News

LGD-6972: Phase II started

September 19, 2016 7:00 AM UTC

Ligand began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 5, 10 and 15 mg oral LGD-6972 once daily for 12 weeks in 148 Type II diabetics inadequately controlled with metformin. ...